Schizoaffective Disorder: Antipsychotic Monotherapy vs. Antipsychotic Plus Mood Stabilizer or Antidepressant
Her psychotic symptoms are controlled, but the depressive episodes that define her diagnosis keep recurring. Whether that calls for a genuinely separate antidepressant or is better handled within the antipsychotic alone is a real, unsettled question.
Y.B., a 29-year-old woman, works part-time at a public library, a role she took specifically because its quiet, structured pace helps her manage her illness in a way her previous retail job never did. She was diagnosed with schizoaffective disorder, depressive type, four years ago, defined by psychotic episodes that occur both during and independent of major depressive episodes. Her psychotic symptoms have been well controlled on paliperidone for the past year, but she has now developed her third significant depressive episode since diagnosis — low mood, anhedonia, poor sleep, and passive thoughts that life isn't worth living, without active suicidal intent — occurring this time without any accompanying psychotic symptoms.
Her mother, who lives nearby and has been closely involved since the diagnosis, says this episode feels different from the first two in a way she can't quite articulate — quieter, she says, but somehow more worrying. Schizoaffective disorder's hybrid nature is exactly what makes this decision genuinely contested rather than protocol-driven: some clinicians favor antipsychotic monotherapy even through depressive episodes, reasoning that many second-generation antipsychotics have some independent mood-stabilizing or antidepressant-adjacent properties and that adding a separate antidepressant risks destabilizing psychotic control or precipitating mania-like activation in a vulnerable patient. Others favor adding a dedicated antidepressant specifically because the depressive episodes here are a core, defining feature of her diagnosis, not an incidental comorbidity, and undertreating them because the primary label includes the word 'psychotic' would mean systematically undertreating half of what schizoaffective disorder actually is for her.
Add an antidepressant, or optimize the antipsychotic
This is her third depressive episode, and antipsychotic-alone management hasn't prevented it happening again. I'd add an SSRI now rather than repeat the same approach a third time — her depressive episodes are as core to this diagnosis as the psychotic ones, and treating them as secondary hasn't worked for her specifically.
I'd flag the real caution honestly, on both sides of it. Helfer and colleagues' meta-analysis, published in the American Journal of Psychiatry, pooled dozens of randomized trials of antidepressants added to antipsychotics and actually found they didn't worsen psychosis in aggregate — the destabilization risk is smaller in the real data than the folk caution suggests. But most of those individual trials were small, and many ran only a few weeks, so "low risk in aggregate" isn't the same as "no risk for her specifically." I don't think that should block the decision, but she deserves to hear both halves of that, not just the reassuring one.
Worth adding the piece that actually matches her picture most closely: that same body of trials found SSRIs specifically effective for depressive symptoms when the analysis was limited to patients who have both schizophrenia and depression — not the broader, more mixed population the headline finding covers. That's her exact situation, not an adjacent one. Given that and the low aggregate risk you're describing, I'd add it — but I'd still want her psychotic symptoms monitored explicitly and more frequently through the first several weeks, not just her depressive symptoms. That's the direct mitigation for the individual-level uncertainty, not a reason to hold off.
Agreed: continue paliperidone unchanged, add an SSRI for the current depressive episode, and schedule more frequent visits for the first six weeks to monitor for both depressive response and any sign of psychotic destabilization.
Not settled as a general policy, only for this episode: whether future depressive episodes should default to adding an antidepressant sooner given this history, or whether each episode should be assessed independently — the team left that broader question open rather than deciding it as a standing rule today.